Agilent Technologies Announces Twist Bioscience Agrees to Pay $22.5 Million Settlement in IP Litigation
February 06 2020 - 5:17PM
Business Wire
Agilent Technologies Inc. (NYSE: A) today announced it has
reached an agreement with Twist Bioscience under which Twist has
agreed to pay Agilent a sum of $22.5 million to settle Agilent’s
claims against Twist, as well as current and former Twist employees
Emily Leproust, Siyuan Chen, and Solange Glaize. The claims
included trade secret misappropriation claims against Twist, Dr.
Leproust, Dr. Chen and Ms. Glaize, breach of contract claims
against Dr. Leproust, Dr. Chen and Ms. Glaize, and breach of duty
of loyalty claims against Dr. Leproust. The settlement agreement
provides a license to Twist for discrete aspects of Agilent’s
oligo-synthesis technology and successfully resolves all
outstanding litigation between all parties.
“This settlement vindicates Agilent’s deep commitment to
protecting our intellectual property,” said Simone Schiller,
associate vice president and managing counsel for Global Litigation
at Agilent. “Agilent is in the business of innovation and driving
technology forward the right way is central to what we do. From the
outset, our goal has been to protect our proprietary technology and
the hard work of the many scientists and engineers who built it.
This settlement accomplishes that.”
The promise and potential applications of synthetic biology are
world-changing, from manufacturing chemicals and biofuels to
providing breakthroughs in detecting and treating diseases. Agilent
is extremely proud of its R&D track record, and of the
important contributions the company is making through its
pioneering oligo-synthesis technology. This leading technology
enables Agilent customers to make new and wide-ranging scientific
discoveries, including groundbreaking research and development
aimed at improving health and saving lives. Agilent welcomes
competition on its merits and looks forward to continuing to drive
innovation in this exciting new area. Agilent’s goal is, and
remains, the advancement of science.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics and applied chemical markets. Now in its 20th
year as an independent company delivering insight and innovation
toward improving the quality of life, Agilent instruments,
software, services, solutions and people provide trusted answers to
customers' most challenging questions. The company generated
revenue of $5.16 billion in fiscal 2019 and employs 16,300 people
worldwide. Information about Agilent is available at
www.agilent.com. To receive the latest Agilent news, subscribe to
the Agilent Newsroom.
Follow Agilent on LinkedIn, Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200206005994/en/
INVESTOR CONTACT: Ankur Dhingra +1 408-345-8948
ankur_dhingra@agilent.com
MEDIA CONTACT: Tom Beermann +1 408-553-2914
tom.beermann@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Sep 2023 to Sep 2024